A long-awaited update from Amgen’s Kras inhibitor shows waning single-agent efficacy – a situation apparently pre-empted by Mirati.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.